Philadelphia (September 28, 2018) – Fox Chase Cancer Center is pleased to announce that its scientists and clinicians earned several newly issued patents during fiscal years 2017 and 2018, the latter of which ended June 30, 2018. The patents, along with the inventors’ names and issue dates, are listed below.
Astsaturov Igor, Khazak Vladimir, and Serebriiski Ilya, “Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors”, US Patent# 9,993,458 B2, issued Jun 12, 2018
Borghaei Hossein and Weiner Louis M., “Antibodies to Tumor Endothelial Marker 7R”, US Patent# 9,534,050 B2, issued Jan 03, 2017
Adams Gregory P., Simmons Heidi H., Robinson Matthew K., Dunbrack Roland, and Lehmann Andreas, “Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies” US Patent# 9,611,321 B2, issued Apr 04, 2017
Hensley Harvey and Roder Navid, “Systems for fusion of fluorescence molecular tomography and magnetic resonance images”, US Patent# 9,629,549 B2, issued Apr 25, 2017
Skalka Anna Marie, Andrake Mark, and Bojja Ravi Shankar, ” Inhibition of human immunodeficiency virus integrase reaching dimer formation utilizing single-chain variable antibodies”, US Patent# 9,533,040 B2, issued Jan 03, 2017
Yang Zeng-Jie, “Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma”, US Patent# 9,616,056 B2 issued Apr 11, 2017
Yen Timothy and Bhattacharjee Vikram, “Combined Inhibition of the Vitamin D Receptor and Poly(ADP)Ribose Polymerase (PARP) in the Treatment of Cancer”, US Patent# 9,889,141 B2 issued on Feb 13, 2018